Lilly is affirming its place at the forefront of the global obesity drug race by exporting its U.S. consumer-focused playbook to Europe, Asia, the Middle East , and beyond.
As demand for anti-obesity medication surges, propelled by blockbuster treatments like Mounjaro and a new generation of GLP-1 therapies , Lilly is making strategic moves to secure dominance in markets worth billions and growing rapidly. Replicating U.S.
direct-to-patient telehealth, digital marketing, and rapid e-commerce accessibility in countries where insurance coverage for obesity drugs is limited and out-of-pocket payment is common. International president Patrik Jonsson emphasizes that this digital-first strategy is being mirrored in Europe, Asia, and the Middle East.
The brand is quickly building scale in the UK, China, the UAE, and Australia , connecting with patients through local partnerships, digital clinics, and global telehealth platforms.
Strategic E-Commerce and Telehealth Partnerships A key pillar of this expansion is Lilly’s alliances with digital health leaders and e-commerce juggernauts such as Alibaba and JD.com in China .
This allows the company to deliver everything from virtual consultations to prescriptions, purchases, and medication delivery in a seamless patient journey…
